RxDoctor Payments Data

Jessica Rumpca

Family · Pierre, SDNPI 1326518556

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 147 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,365in general payments, 2019–2025

Across 147 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$544
  • Amgen$372
  • Pfizer$251
  • Boehringer Ingelheim$171
  • Astellas Pharma US Inc$168
  • Daiichi Sankyo Inc.$128
  • plus $731 from 15 others

What the payments were for

  • Food & beverage$2,365100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,365 in reported general payments places this provider in the 90th percentile of 588 family providers in South Dakota.

See all family providers in South Dakota

Medicare billing

Part B allowed, 2024
$46,106
Medicare patients
181
Services billed
612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$34,216
EliquisApixaban26$23,754
FarxigaDapagliflozin Propanediol14$13,654
JardianceEmpagliflozin18$13,218
Soliqua 100-33Insulin Glargine/Lixisenatide14$11,975
Praluent PenAlirocumab11$5,464
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$5,105
Atorvastatin Calcium170$1,666
Metoprolol Succinate84$1,625
SynthroidLevothyroxine Sodium11$1,401
Levothyroxine Sodium181$1,356
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,262
Rosuvastatin Calcium142$1,075
Sertraline Hcl73$1,021
Valsartan30$1,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$100$34,21640 claims
PfizerEliquis$251$23,75426 claims
Boehringer IngelheimJardiance$171$13,21818 claims
AbbVieSynthroid$18$1,40111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 588 family providers in South Dakota.

Other family in Pierre

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →